It would increase apoptosis of MM cells and as such decrease tumor growth, it would reduce secretion of Dkk1 in the BM microenvironment and thereby restrict osteolytic bone disease, and it would reduce CAM-DR in MM and thereby facilitate a more successful and prolonged response to already established drug treatment options. This evidence concerns the gene DKK1 and neoplasm.